{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:54:55Z","timestamp":1790776495528,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["820755"],"award-info":[{"award-number":["820755"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Recent estimates of the cost-of-illness of community-acquired acute respiratory tract infections (CA-ARTI) are scarce. The current study aimed to estimate country-specific prescriptions, consultations, and productivity loss of patients with CA-ARTI in primary care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were collected via baseline data and a patient diary alongside the PRUDENCE trial. This multinational clinical trial recruited patients visiting their general practitioner (GP) with CA-ARTI symptoms in ten countries. Data collected included the antibiotic class prescribed, consultations with healthcare providers, non-antibiotic medication prescribed for CA-ARTI, disease duration, and missed working hours. Hours of work missed due to the disease were multiplied by country-specific hourly labour cost to calculate productivity loss in terms of absenteeism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Proportions of CA-ARTI patients receiving an antibiotic prescription ranged from 37.2% in Germany to 68.2% in Ireland. Broad-spectrum penicillin was the most frequently prescribed class in Belgium, Germany, and Ireland (&gt;\u200940%), whereas macrolides were most frequently prescribed in Georgia, Greece, and Hungary (&gt;\u200936%). On average, approximately 50% of patients reported having a follow-up consultation with their GP within two weeks of the initial appointment. On average, work missed due to CA-ARTI was 15.4\u00a0h among employed patients, resulting in an average productivity loss of \u20ac358 per patient, and ranged from \u20ac1260 in Germany to \u20ac24 in Georgia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Antibiotic prescriptions, healthcare use, and missed work hours for CA-ARTI were substantially different across participating countries. This study adds valuable information on the generalizability of health economic evidence regarding CA-ARTI between countries and indicates the relevance to collect country-specific data and perform country-specific health economic analyses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10198-026-01992-7","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:57:31Z","timestamp":1790773051000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Consultations, (antibiotic) prescriptions, and productivity losses of patients with community-acquired respiratory tract infection: country-specific findings from the PRUDENCE trial"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9785-945X","authenticated-orcid":false,"given":"Clazinus","family":"Veijer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pim W. M.","family":"Van Dorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Van Der Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alike W.","family":"Van Der Velden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten J.","family":"Postma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette D. I.","family":"Van Asselt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"1992_CR18","doi-asserted-by":"publisher","first-page":"205031212312152","DOI":"10.1177\/20503121231215236","volume":"11","author":"TF Anagaw","year":"2023","unstructured":"Anagaw TF, Melaku E, Mazengia, Bogale EK, Talie Fenta E, Eshetu HB and Kebede N et al (2023) Health-seeking behavior among non-communicable disease patients globally, systematic review and meta-analysis. SAGE Open Med 11:20503121231215236. https:\/\/doi.org\/10.1177\/20503121231215236","journal-title":"SAGE Open Med"},{"key":"1992_CR31","unstructured":"Antimicrobial (2024) consumption and resistance in bacteria from humans and food-producing animals (JIACRA IV \u2013 2019\u2009\u2013\u20092021) [Internet]. [cited 2026 May 11]. Available from: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/antimicrobial-consumption-and-resistance-bacteria-humans-and-food-producing"},{"key":"1992_CR13","unstructured":"Average Sterling exchange rate (2025) Euro XUMAERS - Office for National Statistics [Internet, cited 2025 Aug 4]. Available from: https:\/\/www.ons.gov.uk\/economy\/nationalaccounts\/balanceofpayments\/timeseries\/thap\/mret"},{"issue":"8","key":"1992_CR6","first-page":"494","volume":"6","author":"J Broulette","year":"2013","unstructured":"Broulette J, Yu H, Pyenson B, Iwasaki K and Sato R (2013) The incidence rate and economic burden of community-acquired pneumonia in a working-age population. Am Health Drug Benefits 6(8):494\u2013503","journal-title":"Am Health Drug Benefits"},{"issue":"9","key":"1992_CR1","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s40273-023-01307-1","volume":"41","author":"W Brouwer","year":"2023","unstructured":"Brouwer W, van Baal P (2023) Moving Forward with Taking a Societal Perspective: A Themed Issue on Productivity Costs, Consumption Costs and Informal Care Costs. Pharmacoeconomics 41(9):1027\u20131030. https:\/\/doi.org\/10.1007\/s40273-023-01307-1","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1992_CR35","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s44259-025-00144-w","volume":"3","author":"H Chen","year":"2025","unstructured":"Chen, H., S. A. Sapula, J. Turnidge, and H. Venter. 2025. The effect of commonly used non-antibiotic medications on antimicrobial resistance development in Escherichia coli. Npj Antimicrob Resist 3(1):73. https:\/\/doi.org\/10.1038\/s44259-025-00144-w","journal-title":"Npj Antimicrob Resist"},{"key":"1992_CR28","unstructured":"COVID-19 (2021) How is changing the world: a statistical perspective Volume III [Internet]. Committee for the Coordination of Statistical Activities (CCSA); Available from: https:\/\/ilostat.ilo.org\/topics\/covid-19\/"},{"issue":"4","key":"1992_CR8","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1524-4733.2008.00489.x","volume":"12","author":"M Drummond","year":"2009","unstructured":"Drummond, M., M. Barbieri, J. Cook, H. A. Glick, J. Lis, and F. Malik et al. 2009. Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force Report. Value In Health : The Journal Of The International Society For Pharmacoeconomics And Outcomes Research 12(4):409\u2013418. https:\/\/doi.org\/10.1111\/j.1524-4733.2008.00489.x","journal-title":"Value In Health : The Journal Of The International Society For Pharmacoeconomics And Outcomes Research"},{"key":"1992_CR14","unstructured":"Employment and Wages (2025) Wages [Internet], [cited Aug 4]. Wages - National Statistics Office of Georgia. Available from: https:\/\/www.geostat.ge\/en\/modules\/categories\/39\/wages"},{"key":"1992_CR3","unstructured":"England NHS (2025) NHS England \u00bb Combined adult and paediatric acute respiratory infection (ARI) hubs [Internet], [cited May 23]. Available from: https:\/\/www.england.nhs.uk\/long-read\/combined-adult-and-paediatric-acute-respiratory-infection-ari-hubs\/"},{"key":"1992_CR29","doi-asserted-by":"publisher","unstructured":"European Foundation for the Improvement of Living and Working Conditions (2024) Regional employment change and the geography of telework in Europe. [Internet]. LU: Publications Office. [cited 2025 Jul 2]. Available from: https:\/\/data.europa.eu\/doi\/https:\/\/doi.org\/10.2806\/815188","DOI":"10.2806\/815188"},{"key":"1992_CR19","first-page":"1","volume-title":"Building primary care in a changing Europe","author":"European Observatory on Health Systems and Policies, editors","year":"2015","unstructured":"European Observatory on Health Systems and Policies, editors (2015) Building primary care in a changing Europe, Observatory studies series vol. 38 1. Copenhagen: European Observatory on Health Systems and Policies"},{"key":"1992_CR16","doi-asserted-by":"publisher","unstructured":"Eurostat (2022) Gender pay gap in unadjusted form by age - NACE Rev. 2 activity (B-S except O), structure of earnings survey methodology [Internet]. Eurostat. [cited 2025 Apr 14]. Available from: https:\/\/ec.europa.eu\/eurostat\/databrowser\/product\/page\/EARN_GR_GPGR2AGhttps:\/\/doi.org\/10.2908\/EARN_GR_GPGR2AG","DOI":"10.2908\/EARN_GR_GPGR2AG"},{"key":"1992_CR11","unstructured":"Eurostat (2025). Hourly labour costs [Internet], [cited 2025 Apr 14]. Available from: https:\/\/ec.europa.eu\/eurostat\/statistics-explained\/index.php?title=Hourly_labour_costs"},{"key":"1992_CR17","unstructured":"Gender pay gap in the UK (2025) Office for National Statistics [Internet], [cited Aug 4]. Available from: https:\/\/www.ons.gov.uk\/employmentandlabourmarket\/peopleinwork\/earningsandworkinghours\/bulletins\/genderpaygapintheuk\/2024#the-gender-pay-gap"},{"issue":"2","key":"1992_CR36","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/fampra\/cmu075","volume":"32","author":"PM Hordijk","year":"2015","unstructured":"Hordijk, P. M., B. D. L. Broekhuizen, C. C. Butler, S. Coenen, M. Godycki-Cwirko, and H. Goossens et al (2015) Illness perception and related behaviour in lower respiratory tract infections\u2014a European study. Family Pract 32(2):152\u2013158. https:\/\/doi.org\/10.1093\/fampra\/cmu075","journal-title":"Family Practice"},{"key":"1992_CR24","doi-asserted-by":"publisher","unstructured":"ISRCTN Registry [Clinical Study Registry] (2025) A study to evaluate diagnostic tests used at the point of care for improving antibiotic prescribing for patients with respiratory tract infections in primary care in Europe [cited Apr 23]. Available from: https:\/\/www.isrctn.com\/ISRCTN13336322https:\/\/doi.org\/10.1186\/ISRCTN13336322","DOI":"10.1186\/ISRCTN13336322"},{"issue":"2","key":"1992_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/0167-6296(94)00044-5","volume":"14","author":"MA Koopmanschap","year":"1995","unstructured":"Koopmanschap, M. A., F. F. Rutten, B. M. van Ineveld, and L. van Roijen. 1995. The friction cost method for measuring indirect costs of disease. J Health Econ 14(2):171\u2013189. https:\/\/doi.org\/10.1016\/0167-6296(94)00044-5","journal-title":"Journal Of Health Economics"},{"key":"1992_CR12","unstructured":"Labour costs and labour income (2025) UK - Office for National Statistics [Internet], [cited Aug 4]. Available from: https:\/\/www.ons.gov.uk\/economy\/economicoutputandproductivity\/productivitymeasures\/datasets\/labourcostsandlabourshare"},{"issue":"7698","key":"1992_CR32","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nature25979","volume":"555","author":"L Maier","year":"2018","unstructured":"Maier, L., M. Pruteanu, M. Kuhn, G. Zeller, A. Telzerow, and E. E. Anderson et al. 2018. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 555(7698):623\u2013628. https:\/\/doi.org\/10.1038\/nature25979","journal-title":"Nature"},{"key":"1992_CR21","doi-asserted-by":"crossref","unstructured":"Miszczy\u0144ska K and Antczak E (2024) The Determinants of Presenteeism in Selected European Countries - Modelling from Geographical and Gender Perspectives. Cent Eur J Econ Model Econom 2024 No 2 191\u2013225 [Internet], [cited 2025 Jul 9]. Available from: https:\/\/journals.pan.pl\/dlibra\/publication\/152689\/edition\/133035","DOI":"10.24425\/cejeme.2024.152689"},{"key":"1992_CR20","unstructured":"NHS (2025) England Pharmacy First [Internet], [cited Aug 8]. Available from: https:\/\/www.england.nhs.uk\/primary-care\/pharmacy\/pharmacy-services\/pharmacy-first\/"},{"key":"1992_CR15","unstructured":"Official exchange rate of LARI against foreign currencies [Internet], [cited 2025 Aug 4]. The National Bank of Georgia. Available from: https:\/\/nbg.gov.ge\/en\/monetary-policy\/currency"},{"issue":"suppl2","key":"1992_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/jac\/dkx502","volume":"73","author":"KB Pouwels","year":"2018","unstructured":"Pouwels, K. B., F. C. K. Dolk, D. R. M. Smith, J. V. Robotham, and T. Smieszek. 2018. Actual versus ideal antibiotic prescribing for common conditions in English primary care. Journal Of Antimicrobial Chemotherapy 73(suppl2):19\u201326. https:\/\/doi.org\/10.1093\/jac\/dkx502","journal-title":"Journal Of Antimicrobial Chemotherapy"},{"issue":"6","key":"1992_CR27","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1093\/eurpub\/ckad136","volume":"33","author":"B Read","year":"2023","unstructured":"Read, B., M. McLeod, S. Tonkin-Crine, D. Ashiru-Oredope, A. Quigley, and C. S. Brown et al. 2023. Changes in public health-seeking behaviours for self-limiting respiratory tract infections across England during the COVID-19 pandemic. Eur J Public Health 33(6):987\u2013993. https:\/\/doi.org\/10.1093\/eurpub\/ckad136","journal-title":"Eur J Public Health"},{"issue":"7","key":"1992_CR4","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1080\/13696998.2020.1736872","volume":"23","author":"JE Schneider","year":"2020","unstructured":"Schneider JE, BoehmeC, Borisch B and Dittrich S (2020) Application of a simple point-of-care test to reduce UK healthcare costs and adverse events in outpatient acute respiratory infections. J Med Econ 23(7):673\u2013682. https:\/\/doi.org\/10.1080\/13696998.2020.1736872","journal-title":"Journal Of Medical Economics"},{"issue":"6","key":"1992_CR25","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s10198-024-01746-3","volume":"26","author":"S Siaba","year":"2025","unstructured":"Siaba, S., and B. Casal. 2025. Economic and human burden attributable to antimicrobial resistance in Spain: a holistic macro-estimation of costs. Europ J Health Econ 26(6):893\u2013926. https:\/\/doi.org\/10.1007\/s10198-024-01746-3","journal-title":"The European Journal Of Health Economics"},{"issue":"10","key":"1992_CR26","doi-asserted-by":"publisher","first-page":"e674","DOI":"10.1016\/S2666-7568.(22)00186-6","volume":"3","author":"YY Tan","year":"2022","unstructured":"Tan, Y. Y., V. Papez, W. H. Chang, S. H. Mueller, S. Denaxas, and A. G. Lai. 2022. Comparing clinical trial population representativeness to real-world populations: an external validity analysis encompassing 43 895 trials and 5 685 738 individuals across 989 unique drugs and 286 conditions in England. Lancet Healthy Longev 3(10):e674\u2013e689. https:\/\/doi.org\/10.1016\/S2666-7568.(22)00186-6","journal-title":"Lancet Healthy Longev"},{"issue":"8","key":"1992_CR5","doi-asserted-by":"publisher","first-page":"e71375","DOI":"10.1371\/journal.pone.0071375","volume":"8","author":"A Tichopad","year":"2013","unstructured":"Tichopad A. Roberts C, Gembula I, Hajek P, Skoczynska A and Hryniewicz W et al (2013) Clinical and Economic Burden of Community-Acquired Pneumonia among Adults in the Czech Republic, Hungary, Poland and Slovakia. PLOS ONE 8(8):e71375. https:\/\/doi.org\/10.1371\/journal.pone.0071375","journal-title":"PLOS ONE"},{"key":"1992_CR2","unstructured":"Trueman D, Woodcock F Hancock E (n.d.) Estimating the economic burden of respiratory illness in the UK [Internet]. Available from: https:\/\/www.asthmaandlung.org.uk\/economic-burden-report"},{"key":"1992_CR22","doi-asserted-by":"publisher","unstructured":"van der Velden AW, van de Pol AC, Bongard E, Cianci D, Aabenhus R and Balan A et al (2022) Point-of-care testing, antibiotic prescribing, and prescribing confidence for respiratory tract infections in primary care: a prospective audit in 18 European countries. BJGP Open 6(2). https:\/\/doi.org\/10.3399\/BJGPO.20210212","DOI":"10.3399\/BJGPO.20210212"},{"key":"1992_CR9","doi-asserted-by":"publisher","unstructured":"van der Velden, A. W., S. Coenen, E. Harper, M. Anastasaki, S. Anthierens, and F. B\u00f6hmer et al. 2026. Point-of-care testing strategy versus usual care to safely reduce antibiotic prescribing for acute respiratory tract infections in primary care (PRUDENCE): a pragmatic, randomised controlled trial in 13 countries. Lancet Prim Care 2(2). https:\/\/doi.org\/10.1016\/j.lanprc.2025.100104","DOI":"10.1016\/j.lanprc.2025.100104"},{"issue":"3","key":"1992_CR23","doi-asserted-by":"publisher","first-page":"572","DOI":"10.3390\/antibiotics12030572","volume":"12","author":"A Vellinga","year":"2023","unstructured":"Vellinga, A., A. Luke-Currier, N. Garz\u00f3n-Orjuela, R. Aabenhus, M. Anastasaki, and A. Balan et al. 2023. Disease-Specific Quality Indicators for Outpatient Antibiotic Prescribing for Respiratory Infections (ESAC Quality Indicators) Applied to Point Prevalence Audit Surveys in General Practices in 13 European Countries. Antibiot Basel Switz 12(3):572. https:\/\/doi.org\/10.3390\/antibiotics12030572","journal-title":"Antibiot Basel Switz"},{"key":"1992_CR33","doi-asserted-by":"publisher","unstructured":"Verma T, Bhaskarla C, Sadhir I, Sreedharan S and Nandi D (2018) Non-steroidal anti-inflammatory drugs, acetaminophen and ibuprofen, induce phenotypic antibiotic resistance in Escherichia coli: roles of marA and acrB. Fems Microbiol Lett 365(22). https:\/\/doi.org\/10.1093\/femsle\/fny251","DOI":"10.1093\/femsle\/fny251"},{"issue":"5","key":"1992_CR34","doi-asserted-by":"publisher","first-page":"e2208344120","DOI":"10.1073\/pnas.2208344120","volume":"120","author":"Y Wang","year":"2023","unstructured":"Wang, Y., Z. Yu, P. Ding, J. Lu, L. Mao, and L. Ngiam et al. 2023. Antidepressants can induce mutation and enhance persistence toward multiple antibiotics. Proc Natl Acad Sci U S A 120(5):e2208344120. https:\/\/doi.org\/10.1073\/pnas.2208344120","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1992_CR37","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1186\/s12889-019-7138-x","volume":"19","author":"RK Webster","year":"2019","unstructured":"Webster, R. K., R. Liu, K. Karimullina, I. Hall, R. Aml\u00f4t, and G. J. Rubin (2019) A systematic review of infectious illness Presenteeism: prevalence, reasons and risk factors. Bmc Publ Health 19(1):799. https:\/\/doi.org\/10.1186\/s12889-019-7138-x","journal-title":"Bmc Public Health"},{"key":"1992_CR7","doi-asserted-by":"publisher","unstructured":"Zhang, S., P. Wahi-Singh, B. Wahi-Singh, A. Chisholm, P. Keeling, and H. Nair (n.d.) Costs of management of acute respiratory infections in older adults: A systematic review and meta-analysis. J Glob Health 12:04096. https:\/\/doi.org\/10.7189\/jogh.12.04096","DOI":"10.7189\/jogh.12.04096"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-026-01992-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10198-026-01992-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-026-01992-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:57:36Z","timestamp":1790773056000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10198-026-01992-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":37,"alternative-id":["1992"],"URL":"https:\/\/doi.org\/10.1007\/s10198-026-01992-7","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The PRUDENCE trial was registered with the International Standard Randomised Controlled Trial Number: SRCTN13336322. The trial was approved by the Sponsor\u2019s Research Ethics Committee (REC ref: 20\/NW\/0385), and thereafter by RECs in each participating country.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Clazinus Veijer, Pim W.M. van Dorst, Simon van der Pol, Alike W. van der Velden, and Antoinette D.I. van Asselt declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Maarten J. Postma reports grants and honoraria from various pharmaceutical companies, inclusive those potentially interested in the subject matter of this paper.","order":4,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}